drugset / Trial / NCT04996160
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To learn more about the biological effects of palbociclib on the cells in your body
Timeline
- Start
- 2021-07-09
- Primary completion
- 2023-10-16
- Completion
- 2023-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 75 mg/m2 | Oral |
| Subject | Palbociclib | Small molecule | 100 mg/m2 | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Background | Dexamethasone | Small molecule | 8 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | — |